

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM799370

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
MIDCAP FINANCIAL TRUST, as Agent		03/29/2023	Statutory Trust: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	APTEVO RESEARCH AND DEVELOPMENT LLC		
<b>Street Address:</b>	2401 4th Ave, Suite 1050		
<b>City:</b>	Seattle		
<b>State/Country:</b>	WASHINGTON		
<b>Postal Code:</b>	98121		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>Name:</b>	APTEVO THERAPEUTICS INC.		
<b>Street Address:</b>	2401 4th Ave, Suite 1050		
<b>City:</b>	Seattle		
<b>State/Country:</b>	WASHINGTON		
<b>Postal Code:</b>	98121		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 7</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86974244	ADAPTIR	
<b>Serial Number:</b>	88942264	ADAPTIR	
<b>Serial Number:</b>	86859161	APTEVO BIOTHERAPEUTICS	
<b>Serial Number:</b>	86859136	APTEVO RESEARCH AND DEVELOPMENT	
<b>Serial Number:</b>	86768978	APTEVO THERAPEUTICS	
<b>Serial Number:</b>	86823176		
<b>Serial Number:</b>	88664224	VYDAPTIV	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6179518736		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	6173417729		
<b>Email:</b>	katarzyna.gaysunas@morganlewis.com		

CH \$190.00 86974244

**Correspondent Name:** Katarzyna Gaysunas  
**Address Line 1:** 1 Federal St  
**Address Line 2:** c/o Morgan, Lewis & Bockius LLP  
**Address Line 4:** Boston, MASSACHUSETTS 02110-1726

**NAME OF SUBMITTER:** Katarzyna Gaysunas

**SIGNATURE:** /Katarzyna Gaysunas/

**DATE SIGNED:** 03/31/2023

**Total Attachments: 5**

source=MidCap - Aptevo II - IP Release and Termination\_#page1.tif  
source=MidCap - Aptevo II - IP Release and Termination\_#page2.tif  
source=MidCap - Aptevo II - IP Release and Termination\_#page3.tif  
source=MidCap - Aptevo II - IP Release and Termination\_#page4.tif  
source=MidCap - Aptevo II - IP Release and Termination\_#page5.tif

## RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

This Release of Intellectual Property Security Interest, dated as of March 29, 2023, is made by **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust, (“**Agent**”), in favor of **APTEVO RESEARCH AND DEVELOPMENT LLC**, a Delaware limited liability company, and **APTEVO THERAPEUTICS INC.**, a Delaware corporation (collectively, the “**Grantors**” and each, a “**Grantor**”):

WHEREAS, pursuant to that certain Intellectual Property Security Agreement, dated as of August 5, 2020 (as may have been further amended, modified, restated, replaced or supplemented from time to time, the “**IP Security Agreement**”; capitalized terms used herein have the definition provided for in the IP Security Agreement), recorded with the United States Patent and Trademark Office on August 6, 2020 at Reel/Frame No. 7016/0509 (Trademarks) and on August 6, 2020 at Reel/Frame No. 053417/0287 (Patents), each Grantor granted to Agent, on behalf of the Lenders, a security interest in and to all of its right, title and interest in all of such Grantor’s intellectual property, including those listed on Exhibit A through D thereto;

WHEREAS, the Grantors have requested that Agent release its security interest in and to the patent assets as more particularly described on Schedule A attached hereto (the “**Released Patents**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to the trademark assets as more particularly described on Schedule B attached hereto (the “**Released Trademarks**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to the various intellectual property assets set forth in Sections (a) through (j) of the IP Security Agreement (together with the Released Patents and Released Trademarks, the “**Released IP Collateral**”).

NOW, THEREFORE, Agent, without recourse, representation or warranty and at Grantors’ sole cost and expense, hereby releases all of its right, title and interest in and to the Released IP Collateral.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Agent has caused this Release of Intellectual Property Security Interest to be duly executed and delivered by its duly authorized officer as of the date first written above.


**AGENT:**

**MIDCAP FINANCIAL TRUST**

as Agent

By: Apollo Capital Management, L.P.,  
its investment manager

By: Apollo Capital Management GP, LLC,  
its general partner

By:   
\_\_\_\_\_  
Name: Maurice Amsellem  
Title: Authorized Signatory

## Schedule A

### Patents

#### SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION APVO.80182

Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
United States	Expired	69/813,281	12-Jun-2006		
United States	Expired	60/853,587	20-Oct-2006		
United States	Granted	12/304,582	12-Jun-2007	8,469,577	02-Apr-2013
United States	Pending	16/735,694	23-Dec-2019		

#### PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS APVO.80124

Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
United States	Expired	61/478,489	22-Apr-2011		
United States	Granted	13/983,821	03-Mar-2017	9,782,476	10-Oct-2017
United States	Pending	16/871,597	11-May-2020		

#### CD3 BINDING POLYPEPTIDES APVO.80138

Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
United States	Expired	62/221,190	21-Sep-2013		
United States	Pending	15/761,499	21-Sep-2018		

#### CD133 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS APVO.80141

Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
United States	Expired	62/721,198	21-Sep-2015		
United States	Expired	62/397,736	21-Sep-2016		
United States	Expired	62/466,192	02-Mar-2017		
United States	Granted	15/933,324	22-Mar-2018	10,676,533	09-Jun-2020
United States	Pending	16/315,561	21-Sep-2017		

#### ONCOFETAL ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS APVO.80142

(Co-owned with Alligator Bioscience AB)

Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
United States	Expired	82/535,107	20-Jul-2017		
United States	Expired	62/975,829	23-Oct-2017		
United States	Expired	82/648,072	28-Mar-2018		
United States	Granted	16/041,309	20-Jul-2018	11,259,949	26-Mar-2019
United States	Pending	16/281,440	21-Feb-2019		
United States	Pending	16/632,144	20-Jul-2018		

#### 4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS APVO.80146

Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
United States	Pending	62/887,751	12-Aug-2019		
United States	Pending	82/892,318	18-Sep-2019		
United States	Pending	62/911,016	04-Oct-2019		
United States	Pending	83/026,115	24-July-2020		

#### METHODS AND COMPOSITIONS FOR PREVENTING ABSORPTION OF THERAPEUTIC PROTEINS TO DRUG DELIVERY SYSTEM COMPONENTS APVO.80148

Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
United States	Pending	62/960,602	13-Jan-2020		

#### FORMULATIONS FOR PROTEIN THERAPEUTICS

APVO.80147

Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
United States	Pending	02/060,562	13-Jan-2020		

BISPECIFIC SCFV IMMENOFUSION (BIF)

APVO.80149

Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date
United States	Expired	01/649,211	18-May-2012		
United States	Granted (under reexamination)	14/402,009	18-May-2015	9,743,381	29-Aug-2017
United States	Pending reexamination	90/014,165 and 93/014,299	03-May-2019		

B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES

APVO.80100

Country	Application Status	Application Number	Filing Date	Patent Number	Issue Date	Security Interest
United States	Granted	11/493,132	25-Jul-2006	10,387,481	04-Jan-2019	N/A

Schedule B


Trademarks

ADAPTIR						
Country	Trademark Name	Status	Application No.	Filing Date	Registration No.	Registration Date
US	ADAPTIR	Abandoned with Petition to Reinstate pending	86/974,244	13-Apr-2016		
US	ADAPTIR	Pending	86/942,264	01-Jan-2016		

APTEVO BIOTHERAPEUTICS						
Country	Trademark Name	Status	Application No.	Filing Date	Registration No.	Registration Date
US	APTEVO BIOTHERAPEUTICS	Allowed	86/859161	28-Dec-2015		

APTEVO RESEARCH AND DEVELOPMENT						
Country	Trademark Name	Status	Application No.	Filing Date	Registration No.	Registration Date
US	APTEVO RESEARCH AND DEVELOPMENT	Allowed	86/859,136	28-Dec-2015		

APTEVO THERAPEUTICS						
Country	Trademark Name	Status	Application No.	Filing Date	Registration No.	Registration Date
US	APTEVO THERAPEUTICS	Registered	86/768,978	25-Sep-2015	5,341,248	21-Nov-2017

APTEVO LOGO							
Country	Trademark Name	Image	Status	Application No.	Filing Date	Registration No.	Registration Date
US	APTEVO Logo		Registered	86/823,176	17-Nov-2015	5,370,601	02-Jan-2018

YYDAPTIV						
Country	Trademark Name	Status	Application No.	Filing Date	Registration No.	Registration Date
US	YYDAPTIV	Allowed	88/864,224	22-Oct-2019		

Trademark Clearinghouse Registrations (TMCH)						
US	ADAPTIR Trademark Clearinghouse Registration			Active	00170513892841101389	